

Abstract

The global outbreak of mpox necessitated the rapid development of clinical assays for monkeypox virus detection. While the majority of mpox specimens have high viral loads with corresponding early CT values, reports have indicated some specimens with late CT values can represent false positive results. To mitigate this risk, the Centers for Disease Control and Prevention (CDC) published an advisory recommending repeat testing of all specimens with CT values ≥34. However, limited experimental data was available to support this specific cutoff. In this study, we examine whether a more conservative approach in which all specimens with CT 21 values \geq 29 are repeated would improve the detection of potential false positive results. Compared to the CDC algorithm, our approach identified an additional 20% (5/25) of potential false positive results. To assess the impact of this cutoff on laboratory workload, we estimated the expected increase in test volume and turnaround time (TAT) relative to the CDC method. Using a lower repeat threshold, test volume increased by 0.7% and the mean TAT for positive specimens increased by less than 15 minutes. Overall, a lower threshold than recommended by 27 the CDC for repeating late CT mpox specimens may reduce the number of false positives reported while minimally impacting testing volume and TAT.

Introduction

Monkeypox virus (MPXV) is a double stranded DNA virus in the Orthopoxvirus genus, which also includes variola virus, the causative agent of smallpox. In July 2022 the World Health Organization declared a Public Health Emergency of International Concern due to an outbreak of $MPXV$ with sustained human-to-human transmission in multiple non-endemic countries¹. At the beginning of the outbreak, testing capacity in the United States was limited to the Centers for Disease Control and Prevention (CDC) and members of the Laboratory Response Network. In June 2022, clinical laboratories, using the assay developed by the CDC, began adding additional 38 testing capacity². This was followed over the subsequent weeks by other clinical microbiology laboratories that either adapted the CDC assay or validated their own laboratory developed test in 40 accordance with recommendations from the $FDA³$. Additionally, several manufacturers received emergency use authorization (EUA) for orthopoxvirus or MPXV-specific assays following the 42 EUA declaration on September $17th$, 2022. The majority of specimens collected from individuals with mpox have demonstrated high 44 viral loads with corresponding early CT values⁴. However, shortly after the outbreak began, reports of false positive mpox cases began to surface. In a series of three false positive cases, all 46 specimens had late CT values ranging from 34.3 to $36.7⁵$. In September 2022, the CDC 47 published an advisory recommending repeat testing of all specimens with CT values \geq 34⁶. Due to the limited data surrounding the utility of this cutoff, our institution adopted a more 49 conservative strategy of repeating all positive specimens with a $CT \geq 29$ from $9/15/22$ to $11/4/22$. Here we present a retrospective analysis of this data to better understand the clinical and laboratory impact of a more stringent repeat threshold.

Materials and Methods

MPXV PCR testing

A Lower Repeat Threshold Improves Specificity of MPXV Detection

For samples with MPXV detected, the mean CT1 value was 20.5 (SD 4.0) for positives, 34.3 (SD 3.1) for low positives, and 37.6 (SD 3.6) for indeterminate samples. The average CT2 for low positives was 33.9 (SD 3.3). Per our algorithm, repeat testing was not performed for positive samples and CT2 values for indeterminate specimens were set at 50 (i.e. no valid curve). There was good correlation between the CT1 and CT2 of low positive specimens with an r-squared of 0.8 and standard error of 0.03 (Figure 2). During the study period a total of 184 111 specimens were repeated according to our algorithm. While the majority of specimens (86.4%, 159/184) detected MPXV upon repeat testing, 13.6% (25/184) of samples failed to repeat and were subsequently categorized as indeterminate. CT1 values for indeterminate specimens ranged from 29.5 to 44.2. (Figure 3). While 80% (20/25) of these samples were at or above the CDC's recommended repeat threshold of 34, there were five specimens (CT1 values 29.5, 30.8, 31.1, 32.4, 33.3) below this cutoff. Compared to this study's repeat algorithm, the CDC's algorithm had a sensitivity of 100% (95% CI: 97.7% – 100%) and a specificity of 80% (95% CI: 59.3% – 118 93.17%) for MPXV detection in specimens with CT1 values \geq 29.

120 A Lower Repeat Threshold Minimally Impacts Test Volume and Turn-around Times

Discussion

Here we assess over 4,000 MPXV PCR results from a large reference laboratory to examine the impact of repeating late CT specimens on patient results. We found that a reflex CT of 29 as compared to 34 potentially reduces the number of false positive results reported. We also

demonstrate that regardless of the repeat threshold selected, there is minimal impact to testing volume and TAT.

False positive results may be due to a number of pre-analytic factors including 146 mislabeling, sampling error, or contamination of collection devices and reagents^{10,11}. There are also a variety of analytic errors that can occur such as pipetting error and specimen cross-148 contamination¹². From the perspective of a clinical microbiology laboratory, closed tube systems and a reduction in the number of technicians handling the specimen can lower contamination 150 rates; however, no system is perfect¹³. Specific challenges to preventing cross-contamination during the mpox epidemic included the high prevalence of positive samples (18% during the study period) and the relatively high level of MPXV DNA within positive specimens (mean CT of 20.5 for positive specimens). These problems are not unique to MPXV and may be seen in other viruses with extremely high viral loads, such as BK virus. False positive results have previously been shown with PCR assays for BK virus, including on the instrument used in this study^{14}

A central question to this study is whether the specimens we categorized as indeterminate (i.e. those which failed to repeat) represent a false positive result or are an artifact of stochastic effect near the assay's limit of detection (LOD). When validating our assay, we established the 97.5% (39/40 repeats) LOD at 80 copies per reaction which corresponded to an average CT of 39.5 (SD 1.03, 95% CI 37.8 – 41.6). Thus, we are reasonably confident that specimens at or 162 below this CT value should consistently repeat as detected. In this study, 72% (18/25) of indeterminate specimens had a CT value less than our LOD of 39.5. Therefore, we believe the majority of indeterminate results, and in particular those identified only by the lower cutoff, represent false positive results.

While the initial surge of mpox cases has abated, the question of whether this virus will 183 endemically circulate in humans remains^{17,18}. Currently, data from the CDC and our institution show a positivity rate of approximately 10%, arguing that laboratories will continue to face testing challenges related to specimens with late CT values. As these results may have significant 186 social and psychological impact, reducing false positive mpox results is critical^{19,20}. The CDC's recommendations provide a suitable starting point for laboratories performing mpox testing;

- however, each laboratory should carefully inspect the performance of its assay to determine the
- optimal repeat thresholds.

References

- (1) WHO Director-General's statement at the press conference following IHR Emergency
- Committee regarding the multi-country outbreak of monkeypox 23 July 2022.
- https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-
- the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-
- outbreak-of-monkeypox--23-july-2022 (accessed 2023-06-19).
- (2) Affairs (ASPA), A. S. for P. HHS Expanding Monkeypox Testing Capacity to Five
- Commercial Laboratory Companies. HHS.gov.
- https://www.hhs.gov/about/news/2022/06/22/hhs-expanding-monkeypox-testing-capacity-
- five-commercial-laboratory-companies.html (accessed 2023-06-19).
- (3) Health, C. for D. and R. Monkeypox (mpox) and Medical Devices. FDA.
- https://www.fda.gov/medical-devices/emergency-situations-medical-devices/monkeypox-
- mpox-and-medical-devices (accessed 2023-09-08).
- (4) Lieberman, N. A. P.; Mathias, P. C.; Bradley, B. T.; Greninger, A. L. Clinical Performance
- and Trends during the First Two Months of Monkeypox Virus PCR Testing at Two United
- States Reference Labs. J. Clin. Microbiol. 2022, 60 (12), e01371-22.
- https://doi.org/10.1128/jcm.01371-22.
- (5) Minhaj, F. S.; Petras, J. K.; Brown, J. A.; Mangla, A. T.; Russo, K.; Willut, C.; Lee, M.;
- Beverley, J.; Harold, R.; Milroy, L.; Pope, B.; Gould, E.; Beeler, C.; Schneider, J.; Mostafa,
- H. H.; Godfred-Cato, S.; Click, E. S.; Borah, B. F.; Galang, R. R.; Cash-Goldwasser, S.;
- Wong, J. M.; McCormick, D. W.; Yu, P. A.; Shelus, V.; Carpenter, A.; Schatzman, S.; Lowe,
- D.; Townsend, M. B.; Davidson, W.; Wynn, N. T.; Satheshkumar, P. S.; O'Connor, S. M.;
- O'Laughlin, K.; Rao, A. K.; McCollum, A. M.; Negrón, M. E.; Hutson, C. L.; Salzer, J. S.;

- Team. Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without
- Known Epidemiologic Link to Monkeypox United States, 2022. MMWR Morb. Mortal.
- Wkly. Rep. 2022, 71 (36), 1155–1158. https://doi.org/10.15585/mmwr.mm7136e1.
- (6) 08/23/2022: Lab Advisory: Mpox Virus Testing Considerations to Prevent False Positive
- Test Results. https://www.cdc.gov/locs/2022/08-23-2022-Lab-Advisory-
- Monkeypox_Virus_Testing_Considerations_Prevent_False_Positive_Test_Results.html (accessed 2023-06-18).
- (7) Li, Y.; Olson, V. A.; Laue, T.; Laker, M. T.; Damon, I. K. Detection of Monkeypox Virus
- with Real-Time PCR Assays. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2006, 36 (3), 194–203. https://doi.org/10.1016/j.jcv.2006.03.012.
- (8) Ma, A.; Bradley, B. T. Clinical Testing of Pediatric Mpox Specimens: Unique Features and
- Challenges in a Low Prevalence Population. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin.

Virol. 2023, 163, 105447. https://doi.org/10.1016/j.jcv.2023.105447.

- (9) R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2023.
- (10) Najat, D. Prevalence of Pre-Analytical Errors in Clinical Chemistry Diagnostic Labs in
- Sulaimani City of Iraqi Kurdistan. PLOS ONE 2017, 12 (1), e0170211.
- https://doi.org/10.1371/journal.pone.0170211.
- (11) Sotoudeh Anvari, M.; Gharib, A.; Abolhasani, M.; Azari-Yam, A.; Hossieni Gharalari, F.;
- Safavi, M.; Zare Mirzaie, A.; Vasei, M. Pre-Analytical Practices in the Molecular
- Diagnostic Tests, A Concise Review. Iran. J. Pathol. 2021, 16 (1), 1–19.
- https://doi.org/10.30699/ijp.2020.124315.2357.

- (12) Taylor, S. C.; Nadeau, K.; Abbasi, M.; Lachance, C.; Nguyen, M.; Fenrich, J. The Ultimate
- qPCR Experiment: Producing Publication Quality, Reproducible Data the First Time.
- Trends Biotechnol. 2019, 37 (7), 761–774. https://doi.org/10.1016/j.tibtech.2018.12.002.
- (13) Rahbari, R.; Moradi, N.; Abdi, M. rRT-PCR for SARS-CoV-2: Analytical Considerations.
- Clin. Chim. Acta Int. J. Clin. Chem. 2021, 516, 1–7.
- https://doi.org/10.1016/j.cca.2021.01.011.
- (14) Fritzsche, A.; Berneking, L.; Nörz, D.; Reucher, S.; Fischer, N.; Roggenkamp, H.;
- Aepfelbacher, M.; Rohde, H.; Pfefferle, S.; Lütgehetmann, M. Clinical Evaluation of a
- Laboratory-Developed Quantitative BK Virus-PCR Assay Using the Cobas® Omni Utility
- Channel. J. Virol. Methods 2021, 290, 114093.
- https://doi.org/10.1016/j.jviromet.2021.114093.
- (15) Health, C. for D. and R. Monkeypox (mpox) Emergency Use Authorizations for Medical
- Devices. FDA. https://www.fda.gov/medical-devices/emergency-use-authorizations-
- medical-devices/monkeypox-mpox-emergency-use-authorizations-medical-devices
- (accessed 2023-09-19).
- (16) Non-Variola Orthopoxvirus and Mpox Virus Laboratory Testing Data | Mpox | Poxvirus |
- CDC. https://www-cdc-gov.ezproxy.lib.utah.edu/poxvirus/mpox/response/2022/2022-lab-
- test.html (accessed 2023-09-08).
- (17) Reardon, S. What Does the Future Look like for Monkeypox? Nature 2022, 610 (7931),
- 250–252. https://doi.org/10.1038/d41586-022-03204-7.
- (18) Mega, E. R. Why Scientists Fear Monkeypox Spreading in Wild Animals. Nature 2022. https://doi.org/10.1038/d41586-022-03048-1.

- (19) Happi, C.; Adetifa, I.; Mbala, P.; Njouom, R.; Nakoune, E.; Happi, A.; Ndodo, N.;
- Ayansola, O.; Mboowa, G.; Bedford, T.; Neher, R. A.; Roemer, C.; Hodcroft, E.; Tegally,
- H.; O'Toole, Á.; Rambaut, A.; Pybus, O.; Kraemer, M. U. G.; Wilkinson, E.; Isidro, J.;
- Borges, V.; Pinto, M.; Gomes, J. P.; Freitas, L.; Resende, P. C.; Lee, R. T. C.; Maurer-Stroh,
- S.; Baxter, C.; Lessells, R.; Ogwell, A. E.; Kebede, Y.; Tessema, S. K.; de Oliveira, T.
- Urgent Need for a Non-Discriminatory and Non-Stigmatizing Nomenclature for
- Monkeypox Virus. PLoS Biol. 2022, 20 (8), e3001769.
- https://doi.org/10.1371/journal.pbio.3001769.
- (20) Turpin, R. E.; Mandell, C.; Camp, A. D.; Davidson Mhonde, R. R.; Dyer, T. V.; Mayer, K.
- H.; Liu, H.; Coates, T.; Boekeloo, B. O. Monkeypox-Related Stigma and Vaccine
- Challenges as a Barrier to HIV Pre-Exposure Prophylaxis among Black Sexual Minority
- Men. Int. J. Environ. Res. Public. Health 2023, 20 (14), 6324.
- https://doi.org/10.3390/ijerph20146324.
-

275

Figure 1 – 7-Day Rolling Averages of Test Volume, Total Positivity Rate, and Low Positivity Rate

Total test volume is represented by the blue line and measured in tests per day on the left Y-axis.

Percent of total tests with MPXV detected (CT1 <50) and percent of specimens falling within the

282 repeat threshold (CT1 \geq 29 and <50) are indicated by the green and red lines, respectively.

Positivity rates are measured relative to the total test volume and mapped to the right Y-axis.

Figure 2 – Variation of CT Values on Repeat Testing

Comparison of CT values for initial (CT1) vs. repeated (CT2) tests during the study period,

288 including both low positive results (CT1 \geq 29 to <50; CT2 <50) and indeterminate results (CT1

289 \geq 29 to <50; CT2 = 50). The CDC's recommended repeat threshold (CT \geq 34) is represented by

red dotted line. Linear best fit line and 95% confidence interval for low positive results are

represented by the blue line and gray shading. R-squared value for low-positive only results was

0.8. The r-squared value decreased to 0.43 when indeterminate results were included.

Figure 3 – Distribution of Indeterminate Results by CT1

Cumulative percentage of indeterminate results in our study distributed by CT1 value. Each point represents one indeterminate result. Red dotted line represents the CDC's recommended repeat 298 testing cutoff (CT \geq 34).

A) Comparison of repeat thresholds on overall test volume based on different levels of mpox prevalence in the test population. Y-axis represent relative increase in volume versus a no-repeat approach. B) Comparison of repeat thresholds on mean in-lab TAT for specimens with MPXV detected based on prevalence. Y-axis represents the mean increase of in-lab TAT in hours versus a no-repeat approach.

Figure 5 – Turn Around Time by Final Result

Breakdown of turn-around time by final assigned result. All times are in hours. Total time

between collection and completion shown on top arrow. Values are provided as mean with

standard deviation in parenthesis.